NCT03863249

Brief Summary

The aim of the study is to develop an in vitro model of growth of oral biofilms, and validate xCELLigence system for the selection of an effective antibiotic treatment for each patient.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Feb 2019

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 8, 2019

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

February 25, 2019

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 5, 2019

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2019

Completed
Last Updated

March 5, 2019

Status Verified

March 1, 2019

Enrollment Period

6 months

First QC Date

February 25, 2019

Last Update Submit

March 3, 2019

Conditions

Keywords

PeriodontitisMicrobiomeDysbiosisHomeostasisDental plaqueAntibiotics

Outcome Measures

Primary Outcomes (4)

  • Clinical measure: Clinical attachment loss (CAL) change

    It is defined as the distance in millimeters between CEJ and the end of the periodontal pocket. The calculation of the depth of the pocket + gingival recession or pocket depth - gingival hyperplasia will be carried out.

    1. Baseline, 2. Reevaluation (60 days after Scale and root planing).

  • Clinical measure: Probing pocket depth (PPD) change

    The probing depth will be measured in six areas (disto-buccal, mediate-vestibular, mesio-buccal, disto-palatal, mid-palatal, and mesio-palatal) of each tooth with Williams PQ-OW 208 396 probe. It will be use with a pressure of 20 grams that is equivalent to the pressure of dropping the weight of the probe without exerting additional pressure.

    1. Baseline, 2. Reevaluation (60 days after Scale and root planing).

  • Clinical measure: Bleeding on probing (BOP) change, Gingival Bleeding Index.

    The "Full mouth bleeding score" (FMBS) will be calculated based on scores of 0 (no bleeding) or 1 (bleeding) after probing depths are checked. Four surfaces per tooth are evaluated: mesial, distal, vestibular and lingual.

    1. Baseline, 2. Reevaluation (60 days after Scale and root planing).

  • O'leary plaque index change

    The percentage of gingival surfaces with presence of plaque in the dentogingival junction of the teeth is found. Four surfaces per tooth are evaluated: mesial, distal, vestibular and lingual.

    1. Baseline, 2. Reevaluation (60 days after Scale and root planing).

Study Arms (3)

The exCELLigence system

ACTIVE COMPARATOR

1. Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease. 2. The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing. 3. The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals. 4. The adjunctive antibiotics selected by 'the exCELLingence' system will be started at the second SRP visit.

Procedure: SCALE AND ROOT PLANINGDrug: ADJUNTIVE ANTIBIOTICSDiagnostic Test: MICROBIAL SAMPLING

Origen

ACTIVE COMPARATOR

1. Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease. 2. The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing. 3. The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals. 4. The adjunctive antibiotics agents selected by 'Origen' laboratories analysis will be started at the second SRP visit.

Procedure: SCALE AND ROOT PLANINGDrug: ADJUNTIVE ANTIBIOTICSDiagnostic Test: MICROBIAL SAMPLING

Echevarne

ACTIVE COMPARATOR

1. Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease. 2. The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing. 3. The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals. 4. The adjunctive antibiotics agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit.

Procedure: SCALE AND ROOT PLANINGDrug: ADJUNTIVE ANTIBIOTICSDiagnostic Test: MICROBIAL SAMPLING

Interventions

SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals. Each session will be carried out with the following materials: - Ultrasound device (SONICflex 2003 / L) and curettes (Hu-Friedy Manufacturing, Illinois, USA).

EchevarneOrigenThe exCELLigence system

The antimicrobial adjunctive agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit. The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN.

EchevarneOrigenThe exCELLigence system
MICROBIAL SAMPLINGDIAGNOSTIC_TEST

1. Before treatment, the 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing. 2. The subgingival microbiota will be harvested from the sampling sites 2 months after the completion of active therapy.

EchevarneOrigenThe exCELLigence system

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects of 40-70 years.
  • No smokers or smokers of less than 10 cigarettes a day.
  • Patients with periodontitis stages III and IV grades A-B.
  • Presence of 20 natural teeth, including at least three molar teeth.
  • Presence of at least 4 sites with at least 6 mm probing depth.
  • Good general health

You may not qualify if:

  • Smokers of more than 10 cigarettes a day.
  • Patients who have received periodontal treatment in the previous 12 months.
  • Patients who have used antibiotics in the last 6 months.
  • Routine use of oral antiseptics and / or during the previous 3 months.
  • Systemic conditions that required antibiotic premedication.
  • Women pregnant or nursing.
  • Medications that could influence the outcome of periodontal therapy.
  • Any known allergies to the test antimicrobial agents.
  • Diabetics.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Marta Reglero Santaolaya

Valencia, 46010, Spain

RECRUITING

MeSH Terms

Conditions

Chronic PeriodontitisAlveolar Bone LossPeriodontitisDysbiosisDental Plaque

Interventions

Weights and MeasuresRoot Planing

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsBone ResorptionBone DiseasesMusculoskeletal DiseasesPeriodontal AtrophyDental DepositsTooth Diseases

Intervention Hierarchy (Ancestors)

Investigative TechniquesDental ScalingDental ProphylaxisPeriodonticsDentistrySubgingival CurettagePreventive Dentistry

Central Study Contacts

ANDRÉS LÓPEZ ROLDÁN, DOCTOR

CONTACT

MARTA REGLERO SANTAOLAYA

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Masking Details
Double-blinding: The researchers who performed the measurements and treatment will be different from those who performed the microbial analysis; the examiner will be blinded during the entire duration of the study about the type of analysis subgingival dental plaque has been undergone.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Double blinded, randomized clinical trial.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

February 25, 2019

First Posted

March 5, 2019

Study Start

February 8, 2019

Primary Completion

August 1, 2019

Study Completion

August 1, 2019

Last Updated

March 5, 2019

Record last verified: 2019-03

Locations